货号:A165844 同义名: HKI-272 maleate
Neratinib maleate(HKI-272) 苹果酸盐是一种口服可用、不可逆且高度选择性的 HER2 和 EGFR 抑制剂,其 IC50 分别为 59 nM 和 92 nM。
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
产品名称 | EGFR/ErbB1 ↓ ↑ | ErbB3 ↓ ↑ | ErbB4 ↓ ↑ | HER2/ErbB2 ↓ ↑ | mutant EGFR ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
WZ-3146 |
++++
EGFR (E746_A750/T790M), IC50: 14 nM EGFR (E746_A750), IC50: 2 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Daphnetin |
+
EGFR, IC50: 7.67 μM |
PKA,PKC | {[allProObj[0].p_purity_real_show]} | ||||||||||||||||
Lifirafenib |
++
EGFR, IC50: 29 nM |
+
EGFR(T790M/L858R), IC50: 495 nM |
{[allProObj[0].p_purity_real_show]} | ||||||||||||||||
PD168393 |
++++
EGFR, IC50: 0.70 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Nazartinib |
++
mutant EGFR, Ki: 0.031 μM |
++
mutant EGFR, Ki: 0.031 μM |
{[allProObj[0].p_purity_real_show]} | ||||||||||||||||
Norcantharidin | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
CL-387785 |
++++
EGFR, IC50: 370 pM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
WHI-P154 |
+++
EGFR, IC50: 4 nM |
Src,VEGFR | {[allProObj[0].p_purity_real_show]} | ||||||||||||||||
Tyrphostin A9 |
+
EGFR, IC50: 460 μM |
PDGFR | {[allProObj[0].p_purity_real_show]} | ||||||||||||||||
AG 555 |
+
EGFR, IC50: 0.7 μM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
AG 494 |
+
EGFR, IC50: 1.2 μM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
AG-556 |
+
EGFR, IC50: 5 μM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
RG13022 |
+
EGFR, IC50: 4 μM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Tyrphostin RG 14620 | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Vandetanib |
+
EGFR, IC50: 500 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
CNX-2006 |
++
mutant EGFR, IC50: <20 nM |
++
mutant EGFR, IC50: <20 nM |
{[allProObj[0].p_purity_real_show]} | ||||||||||||||||
AZD3759 |
++++
EGFR (L858R), IC50: 0.2 nM EGFR (WT), IC50: 0.3 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Erlotinib |
++++
EGFR, IC50: 2 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Saracatinib |
+++
EGFR (L861Q), IC50: 4 nM EGFR, IC50: 5 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
AG1557 | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Rociletinib |
++
EGFR (wt), Ki: 303.3 nM EGFR (L858R/T790M), Ki: 21.5 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
AG490 |
+
EGFR, IC50: 0.1 μM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Cetuximab |
++++
EGFR, Kd: 0.39 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Osimertinib |
++
WT EGFR, IC50: 12.92 nM L858R/T790M EGFR, IC50: 11.44 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Osimertinib mesylate | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Chrysophanol | ✔ | mTOR | {[allProObj[0].p_purity_real_show]} | ||||||||||||||||
PD153035 |
++++
EGFR, Ki: 5.2 pM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Olmutinib | ✔ | BTK | {[allProObj[0].p_purity_real_show]} | ||||||||||||||||
WZ4002 |
++++
EGFR (L858R/T790M), IC50: 8 nM EGFR (L858R), IC50: 2 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Icotinib |
+++
EGFR, IC50: 5 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Desmethyl Erlotinib HCl |
++++
EGFR, IC50: 2 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Cyasterone | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
PP 3 |
+
EGFR tyrosine kinase, IC50: 2.7 μM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
WZ8040 | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
(-)-Epigallocatechin Gallate | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
AG 18 |
+
EGFR, IC50: 35 μM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
O-Desmethyl gefitinib |
++
EGFR, IC50: 36 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Falnidamol | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
AZ-5104 |
++++
EGFR (L861Q) , IC50: <1 nM EGFR (L858R), IC50: 6 nM |
+++
ErbB4, IC50: 7 nM |
BRK | {[allProObj[0].p_purity_real_show]} | |||||||||||||||
Butein | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Genistein | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
SU5214 |
+
EGFR, IC50: 36.7 μM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Naquotinib | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Gefitinib |
++
EGFR, IC50: 15.5 nM |
+
EGFR (858R/T790M), IC50: 823.3 nM |
{[allProObj[0].p_purity_real_show]} | ||||||||||||||||
Theliatinib |
+++
WT EGFR, IC50: 3 nM |
++
EGFR T790M/L858R, IC50: 22 nM |
{[allProObj[0].p_purity_real_show]} | ||||||||||||||||
Lazertinib |
++++
WT EGFR, IC50: 76 nM L858R/T790M EGFR, IC50: 2 nM |
++++
Del19/T790M, IC50: 1.7 nM |
{[allProObj[0].p_purity_real_show]} | ||||||||||||||||
Gefitinib-based PROTAC 3 |
++
EGFR, DC50: 22.3 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
MTX-211 | ✔ | PI3K | {[allProObj[0].p_purity_real_show]} | ||||||||||||||||
(E)-AG 99 | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Licochalcone D | ✔ | PARP,Caspase | {[allProObj[0].p_purity_real_show]} | ||||||||||||||||
Zipalertinib |
+++
EGFR (L861Q), IC50: 4.1 nM EGFR WT, IC50: 8 nM |
+++
HER4, IC50: 4 nM |
++++
EGFR(d746-750), IC50: 1.4 nM EGFR L858R, IC50: 2 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||
JND3229 |
+++
EGFR WT, IC50: 6.8 nM |
++
EGFR L858R/T790M, IC50: 30.5 nM |
{[allProObj[0].p_purity_real_show]} | ||||||||||||||||
Firmonertinib mesylate | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Tyrphostin AG30 | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
EGFR-IN-12 |
++
EGFR, IC50: 21 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Mobocertinib | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
(Rac)-JBJ-04-125-02 | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
(S)-Sunvozertinib | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
BLU-945 | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Poziotinib |
+++
HER1, IC50: 3.2 nM |
++
HER4, IC50: 23.5 nM |
+++
HER2, IC50: 5.3 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||
TAK-285 |
++
EGFR/HER1, IC50: 23 nM |
+
HER4, IC50: 260 nM |
++
HER2, IC50: 17 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||
ARRY-380 analog | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Canertinib |
++++
EGFR, IC50: 1.5 nM |
+++
ErbB2, IC50: 9.0 nM |
{[allProObj[0].p_purity_real_show]} | ||||||||||||||||
Dacomitinib |
+++
EGFR, IC50: 6.0 nM |
+
ErbB4, IC50: 73.7 nM |
+
ErbB2, IC50: 45.7 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||
EGFR/ErbB-2/ErbB-4 inhibitor-2 |
+
ErbB4, IC50: 1.91 μM |
+
ErbB2, IC50: 0.08 μM |
{[allProObj[0].p_purity_real_show]} | ||||||||||||||||
(E/Z)-CP-724714 |
++
HER2/ErbB2, IC50: 10 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Lapatinib |
++
EGFR, IC50: 10.8 nM |
+
ErbB4, IC50: 367 nM |
+++
ErbB2, IC50: 9.2 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||
AEE788 |
++++
EGFR, IC50: 2 nM |
+
HER4/ErbB4, IC50: 160 nM |
+++
HER2/ErbB2, IC50: 6 nM |
c-Fms | {[allProObj[0].p_purity_real_show]} | ||||||||||||||
AV-412 free base |
++++
EGFR, IC50: 0.75 nM |
++
ErbB2, IC50: 19 nM |
++++
EGFRL858R/T790M, IC50: 0.51 nM EGFRT790M, IC50: 0.79 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||
Neratinib |
+
EGFR, IC50: 92 nM |
+
HER2, IC50: 59 nM |
Src | {[allProObj[0].p_purity_real_show]} | |||||||||||||||
BMS-599626 |
++
HER1, IC50: 20 nM |
+
HER4, IC50: 190 nM |
++
HER2, IC50: 30 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||
Tucatinib |
+++
ErbB2, IC50: 8 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Allitinib |
++++
EGFR, IC50: 0.5 nM |
++++
ErbB4, IC50: 0.8 nM |
+++
ErbB2, IC50: 3.0 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||
Pelitinib |
+
EGFR, IC50: 38.5 nM |
+
ErbB2, IC50: 1.255 μM |
Src,Raf | {[allProObj[0].p_purity_real_show]} | |||||||||||||||
Sapitinib |
+++
EGFR, IC50: 4 nM |
+++
ErbB3, IC50: 4 nM |
+++
ErbB2, IC50: 3 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||
CUDC-101 |
+++
EGFR, IC50: 2.4 nM |
++
HER2, IC50: 15.7 nM |
HDAC | {[allProObj[0].p_purity_real_show]} | |||||||||||||||
Varlitinib |
+++
ErbB1, IC50: 7 nM |
++++
ErbB2, IC50: 2 nM |
{[allProObj[0].p_purity_real_show]} | ||||||||||||||||
Afatinib dimaleate |
++++
EGFR (L858R/T790M), IC50: 0.4 nM EGFR (wt), IC50: 0.5 nM |
++
HER2, IC50: 14 nM |
{[allProObj[0].p_purity_real_show]} | ||||||||||||||||
Canertinib dihydrochloride |
+++
EGFR, IC50: 7.4 nM |
+++
ErbB2, IC50: 9 nM |
{[allProObj[0].p_purity_real_show]} | ||||||||||||||||
Allitinib tosylate |
++++
EGFR (T790M/L858R), IC50: 12 nM EGFR, IC50: 0.5 nM |
++++
ErbB4, IC50: 0.8 nM |
+++
ErbB2, IC50: 3.0 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||
Tyrphostin AG 528 |
+
EGFR, IC50: 4.9 μM |
+
HER2, IC50: 2.1 μM |
{[allProObj[0].p_purity_real_show]} | ||||||||||||||||
Afatinib |
++++
EGFR (wt), IC50: 0.5 nM EGFR (L858R), IC50: 10 nM |
++++
ErbB4, IC50: 1 nM |
++
HER2, IC50: 14 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||
Pyrotinib dimaleate |
++
EGFR, IC50: 0.013 μM |
++
HER2, IC50: 0.038 μM |
{[allProObj[0].p_purity_real_show]} | ||||||||||||||||
Epertinib HCl |
++++
EGFR, IC50: 1.48 nM |
+++
HER4, IC50: 2.49 nM |
+++
HER2, IC50: 7.15 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||
Tuxobertinib |
++++
EGFR, Kd: 0.2 nM |
++++
HER2, Kd: 0.76 nM |
{[allProObj[0].p_purity_real_show]} | ||||||||||||||||
ALK-IN-1 |
++
EGFR(C797S/del19), IC50: 138.6 nM EGFR(del19), IC50: 36.8 nM |
ALK | {[allProObj[0].p_purity_real_show]} | ||||||||||||||||
Brigatinib |
+
EGFR(del19), IC50: 39.9 nM EGFR(C797S/T790M/del19), IC50: 67.2 nM |
FLT3,ALK | {[allProObj[0].p_purity_real_show]} | ||||||||||||||||
Avitinib |
++++
EGFR L858R/T790M, IC50: 0.18 nM |
BTK | {[allProObj[0].p_purity_real_show]} | ||||||||||||||||
EAI045 | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Almonertinib | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
BI-4020 |
++++
EGFRdel19 T790M C797S, IC50: 0.2 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
EGFR-IN-7 |
++++
EGFRL858R/T790M, IC50: 0.19 nM EGFRd746-750/T790M/C797S, IC50: 0.26 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 |
产品名称 | HER2 ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Poziotinib |
++++
HER2, IC50: 5.3 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Tyrphostin AG 879 |
+
HER2-Neu, IC50: 1.0 μM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
TAK-285 |
+
HER2, IC50: 17 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
ARRY-380 analog | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Canertinib |
+++
ErbB2, IC50: 9.0 nM |
EGFR | {[allProObj[0].p_purity_real_show]} | ||||||||||||||||
(E/Z)-CP-724714 |
++
HER2/ErbB2, IC50: 10 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Lapatinib |
+++
ErbB2, IC50: 9.2 nM |
EGFR | {[allProObj[0].p_purity_real_show]} | ||||||||||||||||
AEE788 |
++++
HER2/ErbB2, IC50: 6 nM |
EGFR | {[allProObj[0].p_purity_real_show]} | ||||||||||||||||
Neratinib |
+
HER2, IC50: 59 nM |
Src,EGFR | {[allProObj[0].p_purity_real_show]} | ||||||||||||||||
BMS-599626 |
+
HER2, IC50: 30 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Mubritinib |
++++
HER2/ErbB2, IC50: 6.0 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Tucatinib |
+++
ErbB2, IC50: 8 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Sapitinib |
++++
ErbB2, IC50: 3 nM |
EGFR | {[allProObj[0].p_purity_real_show]} | ||||||||||||||||
CUDC-101 |
++
HER2, IC50: 15.7 nM |
HDAC,EGFR | {[allProObj[0].p_purity_real_show]} | ||||||||||||||||
Afatinib dimaleate |
++
HER2, IC50: 14 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Afatinib |
++
HER2, IC50: 14 nM |
{[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Pertuzumab | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
Trastuzumab | ✔ | {[allProObj[0].p_purity_real_show]} | |||||||||||||||||
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 |
描述 | Neratinib (HKI-272) maleate is an orally administered, irreversible inhibitor with high selectivity for HER2 and EGFR, exhibiting IC50 values of 59 nM and 92 nM, respectively. This specificity underlines its potential therapeutic application in targeting certain cancers[1]. |
体内研究 | In vivo, Neratinib (administered at dosages between 0 to 80 mg/kg/day orally for 42 days) has shown to exhibit anticancer activities against cells expressing high levels of HER-2 or EGFR, further affirming its therapeutic potential[1]. |
体外研究 | Importantly, Neratinib shows no inhibitory activity against a range of other serine-threonine kinases and the tyrosine kinase c-Met, indicating its targeted action against HER2 and EGFR without affecting these other kinases[1]. In cellular studies, Neratinib demonstrates a capacity to inhibit the proliferation of cell lines with high HER-2 levels, such as 3T3/neu, SK-Br-3, and BT474, while showing minimal activity in cell lines lacking HER-2 or EGFR expression. This specificity underscores its potential utility in treating cancers with elevated HER-2 or EGFR levels[1]. Neratinib induces cell cycle arrest at the G1-S phase in BT474 cells when administered at concentrations ranging from 0 to 2 nM for 12 to 16 hours, highlighting its impact on cell proliferation dynamics[1]. |
计算器 | ||||
存储液制备 | 1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
1.49mL 0.30mL 0.15mL |
7.43mL 1.49mL 0.74mL |
14.86mL 2.97mL 1.49mL |
CAS号 | 915942-22-2 |
分子式 | C34H33ClN6O7 |
分子量 | 673.115 |
别名 | HKI-272 maleate |
运输 | 蓝冰 |
存储条件 |
粉末 Inert atmosphere,Room Temperature 液体 -20°C:3-6个月-80°C:12个月 |
溶解度 |
DMSO: 250 mg/mL(371.41 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO |
动物实验配方 |